189 related articles for article (PubMed ID: 38459020)
41. BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.
S Soderquist R; Eastman A
Mol Cancer Ther; 2016 Sep; 15(9):2011-7. PubMed ID: 27535975
[TBL] [Abstract][Full Text] [Related]
42. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
43. Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients.
Petrova V; Groth C; Bitsch R; Arkhypov I; Simon SCS; Hetjens S; Müller V; Utikal J; Umansky V
Front Immunol; 2023; 14():1065767. PubMed ID: 36860876
[TBL] [Abstract][Full Text] [Related]
44. Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer.
Chen J; Sun HW; Yang YY; Chen HT; Yu XJ; Wu WC; Xu YT; Jin LL; Wu XJ; Xu J; Zheng L
Signal Transduct Target Ther; 2021 Jan; 6(1):4. PubMed ID: 33414378
[TBL] [Abstract][Full Text] [Related]
45. Icaritin promotes tumor T-cell infiltration and induces antitumor immunity in mice.
Hao H; Zhang Q; Zhu H; Wen Y; Qiu D; Xiong J; Fu X; Wu Y; Meng K; Li J
Eur J Immunol; 2019 Dec; 49(12):2235-2244. PubMed ID: 31465113
[TBL] [Abstract][Full Text] [Related]
46. Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties.
Qiu H; Zmina PM; Huang AY; Askew D; Bedogni B
Cancer Lett; 2018 Oct; 434():144-151. PubMed ID: 30036609
[TBL] [Abstract][Full Text] [Related]
47. Modified Bushen Yiqi formula enhances antitumor immunity by reducing the chemotactic recruitment of M2-TAMs and PMN-MDSCs in Lewis lung cancer-bearing mice.
Kong Q; Zhu H; Gong W; Deng X; Liu B; Dong J
J Ethnopharmacol; 2024 Jan; 319(Pt 1):117183. PubMed ID: 37739106
[TBL] [Abstract][Full Text] [Related]
48. Inhibiting the biogenesis of myeloid-derived suppressor cells enhances immunotherapy efficacy against mammary tumor progression.
Colligan SH; Amitrano AM; Zollo RA; Peresie J; Kramer ED; Morreale B; Barbi J; Singh PK; Yu H; Wang J; Opyrchal M; Sykes DB; Nemeth MJ; Abrams SI
J Clin Invest; 2022 Dec; 132(23):. PubMed ID: 36453551
[TBL] [Abstract][Full Text] [Related]
49. Confounding off-target effects of BH3 mimetics at commonly used concentrations: MIM1, UMI-77, and A-1210477.
Mallick DJ; Soderquist RS; Bates D; Eastman A
Cell Death Dis; 2019 Feb; 10(3):185. PubMed ID: 30796196
[TBL] [Abstract][Full Text] [Related]
50. Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients.
Adamo A; Frusteri C; Pilotto S; Caligola S; Belluomini L; Poffe O; Giacobazzi L; Dusi S; Musiu C; Hu Y; Wang T; Rizzini D; Vella A; Canè S; Sartori G; Insolda J; Sposito M; Incani UC; Carbone C; Piro G; Pettinella F; Qi F; Wang D; Sartoris S; De Sanctis F; Scapini P; Dusi S; Cassatella MA; Bria E; Milella M; Bronte V; Ugel S
Oncoimmunology; 2023; 12(1):2253644. PubMed ID: 37720688
[TBL] [Abstract][Full Text] [Related]
51. Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.
Seiller C; Maiga S; Touzeau C; Bellanger C; Kervoëlen C; Descamps G; Maillet L; Moreau P; Pellat-Deceunynck C; Gomez-Bougie P; Amiot M
Cell Death Dis; 2020 May; 11(5):316. PubMed ID: 32371863
[TBL] [Abstract][Full Text] [Related]
52. Combination of PD-1 Checkpoint Blockade and Botulinum Toxin Type A1 Improves Antitumor Responses in Mouse Tumor Models of Melanoma and Colon Carcinoma.
Kwak S; Lee JY; Kim MJ; Lee HJ; Lee DK; Kang J; Kang WH; Son WC; Cruz DJM
Immunol Invest; 2023 Nov; 52(6):749-766. PubMed ID: 37403798
[TBL] [Abstract][Full Text] [Related]
53. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
54. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
55. Polyamine Blocking Therapy Decreases Survival of Tumor-Infiltrating Immunosuppressive Myeloid Cells and Enhances the Antitumor Efficacy of PD-1 Blockade.
Alexander ET; Mariner K; Donnelly J; Phanstiel O; Gilmour SK
Mol Cancer Ther; 2020 Oct; 19(10):2012-2022. PubMed ID: 32747421
[TBL] [Abstract][Full Text] [Related]
56. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
57. The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation.
Li Y; Acharya G; Elahy M; Xin H; Khachigian LM
Cancer Lett; 2019 Sep; 459():268-276. PubMed ID: 31128215
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA.
Subramanian A; Andronache A; Li YC; Wade M
Oncotarget; 2016 Mar; 7(13):15986-6002. PubMed ID: 26910119
[TBL] [Abstract][Full Text] [Related]
59. Valproic acid attenuates CCR2-dependent tumor infiltration of monocytic myeloid-derived suppressor cells, limiting tumor progression.
Xie Z; Ikegami T; Ago Y; Okada N; Tachibana M
Oncoimmunology; 2020; 9(1):1734268. PubMed ID: 32158627
[TBL] [Abstract][Full Text] [Related]
60. BH3 Mimetics in Hematologic Malignancies.
Klener P; Sovilj D; Renesova N; Andera L
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
